Ablynx is discovering and developing novel, proprietary antibody-like molecules called nanobodies. These nanobodies are being developed both as target validation tools and as therapeutics. The unique properties of nanobodies allow them to perform functions that cannot be undertaken by conventional monoclonal antibodies. The company went public in November 2007.

Location Ghent, Belgium
Website www.ablynx.com